CRISPR Therapeutics
CRSP
39.10
+0.17
+0.44%
CRISPR Therapeutics
US · CRSP
#2057 by market cap
Listed 2016
39.10
+0.17
+0.44%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:54
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 81.12% -0.86pp
- Institutions
- 612 +2
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund61.26%
Hedge Fund6.62%
VC/PE Fund6.05%
Public Company2.95%
Private Company1.95%
Government Pension Fund1.51%
Individual/Insider0.52%
Sovereign Wealth Fund0.30%
Family Office/Trust0.25%
Other18.58%
Top holders as of 2026-09-30
ARK Investment Management LLC
10.37% · 10.06M sh
BlackRock
8.56% · 8.30M sh
Capital Research
6.41% · 6.22M sh
Orbis Investment Management Limited
5.62% · 5.45M sh
State Street Global Advisors
5.15% · 4.99M sh
GSK Equity Investments, Limited
2.69% · 2.61M sh
Geode Capital Management, LLC
2.59% · 2.51M sh
T. Rowe Price Group, Inc.
2.25% · 2.18M sh
SR One Capital Management, LP
2.10% · 2.04M sh
Two Sigma Investments, LP
2.05% · 1.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| Samarth Kulkarni | Chairperson & CEO | 0.32% |
| James Kasinger | General Counsel | 0.10% |
| Douglas Treco | Lead Independent Director | 0.02% |
| Naimish Patel | Chief Medical Officer | 0.02% |
| Ali Behbahani | Independent Director | 0.02% |
| Simeon George | Independent Director | 0.02% |
| Raju Prasad | Officer | 0.02% |
| John Greene | Independent Director | 0.01% |
| Briggs Duncan W. Morrison | Independent Director | 0.01% |
| Katherine High | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Raju Prasad | Officer | Intent to Sell (Form 144) | -79,393 | $49.88 |
| 2026-11-03 | Sivakesava Sakhamuri | Chief Technology Officer | Other Derivative Acquisition | +40,000 | -- |
| 2026-11-03 | Sivakesava Sakhamuri | Chief Technology Officer | Other Derivative Acquisition | +90,000 | $51.78 |
| 2026-10-25 | Samarth Kulkarni | Chairperson & CEO | Other Derivative Acquisition | +28,750 | -- |
| 2026-10-25 | Samarth Kulkarni | Chairperson & CEO | Other Derivative Acquisition | +57,500 | $49.01 |
| 2026-10-25 | Naimish Patel | Chief Medical Officer | Other Derivative Acquisition | +12,000 | -- |
| 2026-10-25 | Naimish Patel | Chief Medical Officer | Other Derivative Acquisition | +24,000 | $49.01 |
| 2026-10-25 | James Kasinger | General Counsel | Other Derivative Acquisition | +9,000 | -- |
| 2026-10-25 | James Kasinger | General Counsel | Other Derivative Acquisition | +18,000 | $49.01 |
| 2026-10-25 | Andrew Silver | CFO, Principal Financial Officer & Principal Accounting Officer | Other Derivative Acquisition | +9,000 | -- |
| 2026-10-25 | Andrew Silver | CFO, Principal Financial Officer & Principal Accounting Officer | Other Derivative Acquisition | +18,000 | $49.01 |
| 2026-10-18 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Sale | -47,837 | $49.78 |
| 2026-10-18 | Andrew Silver | CFO, Principal Financial Officer & Principal Accounting Officer | Other Derivative Acquisition | +25,000 | -- |
| 2026-10-18 | Andrew Silver | CFO, Principal Financial Officer & Principal Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-10-15 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Retained | +52,163 | -- |
| 2026-10-13 | Simeon George | Independent Director | Derivative Exercise and Sale | -14,514 | $14.00–49.63 |
| 2026-10-13 | Simeon George | Independent Director | Derivative Exercise and Retained | +15,486 | $14.00 |
| 2026-10-13 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Sale | -4,098 | $49.26 |
| 2026-10-13 | James Kasinger | General Counsel | Derivative Exercise and Sale | -1,040 | $49.26 |
| 2026-10-12 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Retained | +4,235 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.
CRISPR Therapeutics discussion 0 comments